MyPrurigoTeam

Nemluvio (nemolizumab-ilto) is a biologic drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with prurigo nodularis, a chronic skin condition characterized by intensely itchy nodules. Here are some key points about Nemluvio:

- Mechanism: It works by blocking the activity of IL-31, a Show Full Answer

Nemluvio (nemolizumab-ilto) is a biologic drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with prurigo nodularis, a chronic skin condition characterized by intensely itchy nodules. Here are some key points about Nemluvio:

- Mechanism: It works by blocking the activity of IL-31, a protein in the immune system that plays a key role in the development of itching and inflammation in prurigo nodularis.
- Administration: Nemluvio is administered by subcutaneous injection using a single-dose, prefilled dual-chamber pen. Dosing sizes depend on a person’s weight, with a new dose given every four weeks.
- Side Effects: Common side effects include headache, atopic dermatitis, eczema, and eczema nummular. Rare but serious side effects may include hypersensitivity reactions.
- Cost and Access: While the cost can be high, some patients may have access to programs that provide the medication at no charge for a certain period.

For more detailed information, you can visit the Nemluvio page on MyPrurigoTeam. Always consult with your healthcare provider to discuss treatment options and access programs.

 This AI-generated response comes from MyPrurigoTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Nemluvio (Nemolizumab-Ilto) for Prurigo Nodularis | MyPrurigoTeam

Is Prurigo Nodularis an Autoimmune Disease? | MyPrurigoTeam